Business
Editas Medicine Announces Third Quarter 2021 Results and Business Updates
EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment
About this update from Editas Medicine, Inc.
[{"type":"text","content":"EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric mid-dose cohorts EDIT-301 Phase 1/2 RUBY trial for the treatment of sickle cell disease currently enrolling study participants Presented preclinical data on novel SLEEK gene editing technology enabling high efficiency, multi-transgene knock-in in multiple clinically relevant cell types CAMBRIDGE, Mass., , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2021. “Editas recently marked an important milestone with the presentation of initial EDIT-101 results demonstrating a favorable safely profile and encouraging signals of clinical activity and evidence of ocular gene editing. Encouraged by these data, we look forward to obtaining additional clinical results, including from our ongoing adult high-dose and pediatric mid-dose cohorts,” said James C. Mullen, Chairman, President, and Chief Executive Officer, Editas Medicine. “We have also continued to make excellent progress advancing our broader clinical and preclinical programs, including the expansion of our gene editing capabilities, as exemplified by our proprietary SLEEK knock-in technology, which we are already applying in our iNK program for solid tumors.” Recent Achievements and Outlook In Vivo Gene Edited Medicines EDIT-101 for Leber Congenital Amaurosis 10 (LCA10), a CEP290-Related Retinal Degenerative DisorderInitial clinical data demonstrated favorable safety profile, and efficacy signals in the mid-dose cohort provided initial evidence for clinical benefit Editas Medicine presented initial clinical data from the ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101 for the treatment of LCA10. The data included preliminary patient safety and efficacy assessments on the first two cohorts.No serious adverse events or dose-limiting toxicities were reported in the first six adult subjects treated with the low or mid doses of EDIT-101. In addition, early efficacy signals in the mid dose cohort provided clinical evidence of gene editing and suggest potential clinical benefits. The Company believes these initial data validate Editas Medic...